Home » Topics » BioWorld Science

BioWorld Science
RSS

Syndax and Nektar collaborate to study combination of NKTR-214 with entinostat in melanoma

May 31, 2018

Encouraging results seen with pegilodecakin plus pembrolizumab or nivolumab in NSCLC, RCC patients

May 31, 2018

Five Prime collaborates with Roche on IHC companion diagnostic assays

May 31, 2018

FDA places clinical hold on IND for CTX-001 in sickle cell disease

May 31, 2018

Phase II EQUATOR study of filgotinib in psoriatic arthritis meets primary endpoint

May 31, 2018

Natural killer cell phenotype GAIA-102 has antitumor activity

May 31, 2018

Treeway completes phase I study of oral formulation of TW-001 for ALS

May 31, 2018

Denali Therapeutics exercises option to acquire F-star Gamma

May 31, 2018

Arix, Evotec and Fred Hutchinson establish academic bridge collaboration

May 31, 2018

FDA grants priority review to Fycompa pediatric sNDA

May 31, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...